Antimicrobial resistance (AMR) is a pressing public health issue in Europe, and it's time to shine a light on this hidden danger. Imagine a world where common infections become untreatable, and the medicines we rely on lose their effectiveness. This is the reality we're facing with AMR in foodborne bacteria like Salmonella and Campylobacter.
A recent joint report from the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) reveals a concerning trend. While some countries have made progress in reducing resistance levels in humans and food-producing animals, AMR in these bacteria remains alarmingly high.
Here's where it gets controversial: A significant proportion of Campylobacter and Salmonella from humans and food-producing animals still show resistance to ciprofloxacin, a crucial antimicrobial for treating severe infections. Resistance in Salmonella from food-producing animals has been consistently high, but what's even more worrying is the recent increase in resistance in human Salmonella infections.
This trend is a red flag because it limits our treatment options. In fact, ciprofloxacin is no longer recommended for treating Campylobacter infections in humans due to widespread resistance across Europe. To preserve its effectiveness in human medicine, its use in animals has been restricted.
But here's the part most people miss: AMR isn't just about one antimicrobial. Across Europe, a high proportion of Salmonella and Campylobacter from humans and targeted food-producing animals also show resistance to commonly used antimicrobials like ampicillin, tetracyclines, and sulfonamides.
And it gets even more concerning. The detection of carbapenemase-producing E. coli bacteria in food-producing animals and meat in several countries is a wake-up call. Carbapenems are our last resort for treating human infections, and they're not authorized for use in food-producing animals. The number of reported detections is on the rise, and we need to investigate these sources urgently.
Despite these ongoing concerns, there are glimmers of hope. While a high proportion of Salmonella and Campylobacter remain resistant to commonly used antimicrobials, several countries have reported declining resistance to specific antimicrobials over time. This shows that targeted efforts can make a real difference.
For example, resistance in Salmonella bacteria from humans to ampicillin and tetracyclines has significantly decreased over the past ten years in many countries. Similarly, positive trends have been identified in food-producing animals at the EU level, with decreasing resistance to tetracyclines in broilers and to ampicillin and tetracyclines in turkeys.
For Campylobacter, resistance to erythromycin, a first-line treatment for human infections, has also declined in several countries over the past decade, both in humans and in some food-producing animals.
Additionally, combined resistance to critically important antimicrobials remains generally low in Salmonella, Campylobacter, and E. coli. This means that resistance to multiple antimicrobials at the same time is not widespread, which is a positive sign.
However, we can't become complacent. While some improvements have slowed down, particularly in E. coli, where resistance levels in poultry have stabilized rather than continued to decline, we must continue our efforts. Some countries have successfully reduced antimicrobial resistance in food-producing animals, contributing to an overall improvement at the EU level.
Why is continued action on AMR essential? AMR affects us all. When bacteria become resistant to antimicrobials, infections become harder to treat, and our treatment options become limited. Resistance patterns vary widely, influenced by how we use antimicrobials, farming practices, animal health measures, and infection prevention strategies.
These findings emphasize the importance of a One Health approach, recognizing the interconnectedness of human health, animal health, and food production. While progress has been made, we must continue to use antimicrobials responsibly across all sectors and combine this with effective infection prevention, animal health, and food safety practices. Only then can we slow the emergence and spread of antimicrobial-resistant bacteria and protect public health across Europe.
So, what do you think? Is enough being done to tackle AMR? Share your thoughts in the comments below!
